Augmenix Ranked as One of America’s Fastest-Growing Private Companies
With a Three-Year Sales Growth of 643%, Augmenix is one of the Fastest Growing Private Companies as Recognized by Inc. Magazine
WALTHAM, Mass.–(BUSINESS WIRE)–Inc. magazine has ranked Augmenix in the top 12% on its 35th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, was also ranked in the top 16% of the health sector and in the top 10% for Metro Boston-based companies. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment— its independent small businesses.
“The outstanding sales results are due to our break-through technology that improves radiotherapy outcomes coupled with world-class service.”
“We are honored to be recognized by Inc. magazine as among the nation’s most pioneering and successful private companies,” said John Pedersen, CEO of Augmenix. “The outstanding sales results are due to our break-through technology that improves radiotherapy outcomes coupled with world-class service.”
The Augmenix rapid growth stems from the April 2015 FDA Clearance of its lead product, SpaceOAR System, and continued growth is expected as the company expands its sales force and product offerings. The company will be moving into a new facility in 2017 to accommodate further growth in personnel, production and R&D.
SpaceOAR System is an innovative technology that reduces rectal complications in men undergoing radiation therapy for prostate cancer. Through a percutaneous injection, SpaceOAR hydrogel physically separates the prostate from the rectum during radiotherapy. This space between organs decreases the radiation dose to the rectum, the organ at risk (OAR), and reduces side effects such as rectal bleeding, and pain. SpaceOAR System has been featured in over 50 peer-reviewed publications and conference abstracts, and the ECRI Institute named SpaceOAR System one of the 10 top technological advances to watch in 2016.
“The Inc. 5000 list stands out where it really counts,” says Inc. President and Editor-In-Chief Eric Schurenberg. “It honors real achievement by a founder or a team of them. No one makes the Inc. 5000 without building something great – usually from scratch. That’s one of the hardest things to do in business, as every company founder knows. But without it, free enterprise fails.”
About Inc. Media:
Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders. Winner of the National Magazine Award for General Excellence in both 2014 and 2012. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 15,000,000 today. For more information, visit www.inc.com.
The Augmenix Products
Using a minimally invasive procedure, SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and is then absorbed and cleared in the patient’s urine. See the Instructions for Use for a complete list of warnings, precautions and risks. The SpaceOAR System has FDA clearance, CE mark, and Canadian and TGA approvals. Augmenix also markets TraceIT® Hydrogel, the world’s first absorbable hydrogel tissue marker with CT, MRI and ultrasound visibility. TraceIT Hydrogel is FDA cleared, CE marked and TGA approved, and is finding utility as a marker to improve radiation targeting of bladder tumors.
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.